ClinicalTrials.gov
public full text
Public Domain
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: * Use BRM421 two times a day for at least 12 weeks * Visit the clinic monthly for checkups and tests
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease#863337
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease#1322171
- Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma#1139764
- Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect#888917
- Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)#911296
Record · ID 1229800
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive